The entry of the US investor Morgan Stanley gave the share of MorphoSys AG again a push towards the 20-euro mark. As announced on August 24, Morgan Stanley now holds 6.37% of the shares of the antibody specialist based in Martinsried near Munich. This is the second new major investor within a few months after the introduction of mark Lampert in May. Also the Pharma world shows interest in the unique HuCAL technology as well as the company's drug development pipeline: the next largest shareholders are Novartis (almost 7 percent) and AstraZeneca (almost 5%).
In September, the results from the phase II clinical trial of the proprietary drug candidate MOR 103 are eagerly expected. Positive data could spur the share price further.